Literature DB >> 16793138

Characterization of human monoclonal autoantibody Fab fragments against oxidized LDL.

Young-Eun Jeon1, Chang-Won Seo, Eun Sun Yu, Cheol Joo Lee, Sae-Gwang Park, Young-Ju Jang.   

Abstract

Oxidized low-density lipoprotein (oxLDL) is a key autoantigen in atherosclerosis. The genetic structures and pathogenic roles of autoantibodies against this protein remain to be established. In this study, we cloned several monoclonal IgG autoantibody Fab fragments specific for oxLDL from peripheral blood lymphocytes of atherosclerosis patients, using phage display technology. The sequences of their variable regions were determined at the cDNA level. The closest germline counterparts for the heavy chains belonged to the V(H)3 or V(H)1 family. The sequences and lengths of complementarity-determining regions (CDR)3-V(H) were diverse, and frequent mutations of positively charged amino acids (particularly arginine) over entire V(H) and V(L) sequences were observed. It is proposed that anti-oxLDL autoantibody formation is driven by antigens. Among the Fabs, P2-8 and P3-175 bound to both MDA-LDL and Cu-oxLDL, and inhibited the uptake of oxLDL by macrophages, suggesting the epitope(s) recognized by the Fabs is a part of ligands on oxLDL that is involved in uptake by macrophage scavenger receptor. These human autoantibody Fabs require detailed investigation to ascertain their potential as agents for clinical applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793138     DOI: 10.1016/j.molimm.2006.04.005

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  2 in total

1.  Human monoclonal Fab and human plasma antibodies to carbamyl-epitopes cross-react with malondialdehyde-adducts.

Authors:  Outi Kummu; S Pauliina Turunen; Piotr Prus; Jaakko Lehtimäki; Marja Veneskoski; Chunguang Wang; Sohvi Hörkkö
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

2.  cAb-Rep: A Database of Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody Prevalence.

Authors:  Yicheng Guo; Kevin Chen; Peter D Kwong; Lawrence Shapiro; Zizhang Sheng
Journal:  Front Immunol       Date:  2019-10-09       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.